Cytomegalovirus disease in lung transplantation: Impact of recipient seropositivity and duration of antiviral prophylaxis

Transplant Infectious Disease

Volumn 15, Issue 2, 2013, Pages 163-170

  Hammond, S P ^a,b   Martin, S T ^a   Roberts, K ^a   Gabardi, S ^a   Fuhlbrigge, A L ^a,b   Camp, P C ^a,b   Goldberg, H J ^a,b   Marty, F M ^a,b   Baden, L R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytomegalovirus; Lung transplantation; Prophylaxis

Indexed keywords

COTRIMOXAZOLE; GANCICLOVIR; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LOW DRUG DOSE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT DURATION; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84875947788     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12036     Document Type: Article

References (17)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
2. Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10: 638-644; discussion 645-646.
3. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5: 1462-1468.
4. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635-1642.
5. Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90: 672-676.
6. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28: 670-675.
7. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008; 27: 875-881.
8. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
9. Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011; 30 (9): 990-996.
10. Mitsani D, Nguyen MH, Kwak EJ, et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant 2010; 29: 1014-1020.
11. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
12. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229-1242.
13. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
14. Koo S, Kubiak DW, Issa NC, et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation 2012; 94 (3): 281-286.
15. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
16. Brennan DC, Flavin K, Lowell JA, et al. A randomized double-blinded comparison of thymoglobulin vs. Atgam for induction immunsuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
17. Snyder LD, Finlen Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391-1396.